paroxetine has been researched along with Central Nervous System Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baryshnikova, E; Bellissima, V; Gabriella Tina, L; Gavilanes, D; Gazzolo, D; Godos, J; Nigro, F; Pluchinotta, F; Varrica, A; Ververs, T; Visser, GHA | 1 |
| Pinkofsky, HB; Reeves, RR | 1 |
| Ewald, R; Frank, UG; Joos, AA; Kaschka, WP; König, F; Mörike, KE | 1 |
| Cohen, CI; Trappler, B | 1 |
| Buchalter, EN; Giambanco, V; Lantz, MS | 1 |
| Anand, VS; Dewan, MJ | 1 |
1 trial(s) available for paroxetine and Central Nervous System Disease
| Article | Year |
|---|---|
Use of SSRIs in "very old" depressed nursing home residents.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Diseases; Dementia, Vascular; Depressive Disorder; Female; Fluoxetine; Homes for the Aged; Humans; Male; Matched-Pair Analysis; New York; Nursing Homes; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Statistics, Nonparametric | 1998 |
5 other study(ies) available for paroxetine and Central Nervous System Disease
| Article | Year |
|---|---|
Antenatal maternal antidepressants drugs treatment affects S100B levels in maternal-fetal biological fluids in a dose dependent manner.
Topics: Adult; Amniotic Fluid; Antidepressive Agents; Biomarkers; Central Nervous System Diseases; Clinical Laboratory Techniques; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Maternal-Fetal Relations; Paroxetine; Pregnancy; S100 Calcium Binding Protein beta Subunit | 2020 |
Lhermitte's sign in paroxetine withdrawal.
Topics: Adult; Central Nervous System Diseases; Depressive Disorder; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1996 |
Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Blood Pressure; Central Nervous System Diseases; Clozapine; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Dysthymic Disorder; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1997 |
Serotonin syndrome following the administration of tramadol with paroxetine.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Autonomic Nervous System Diseases; Central Nervous System Diseases; Depression; Drug Interactions; Female; Humans; Pain; Paroxetine; Selective Serotonin Reuptake Inhibitors; Syndrome; Tramadol | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |